STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial
On Tuesday, Sellas said the therapy, called galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia (AML) — an outcome that achieved the main goal of a Phase 3 clinical trial, the company said.
- Continue to STAT+ to read the full story….
It looks like I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy.
In a column published in September, I predicted galinpepimut would fail to prolong survival in the Phase 3 study.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →